Interleukin-10 as a Potential Immunosuppressor in Patients with Human Immunodeficiency Virus and Its Modulation After the First Cycle of Autovaccination Treatment
Lymphocytes from HIV-infected patients before and after the first cycle of AUVA treatment were tested for their cytokine release pattern. Patients with more than 200 CD4+ cells/µl responded with increased or constant levels of interleukin (IL)-10 but decreased levels of tumor necrosis factor (TNF) alpha after in vitro stimulation with 10% AUVA material. These patients responded with increased or constant levels of CD4+ cells during the first course of treatment. Patients with less than 200 CD4+ cells never showed a positive IL-10 response but presented with reduced TNF alpha production in vitro if positive levels had been detected before. These data are consistent with the interpretation that AUVA directly downmodulates TNF alpha production by increased production of IL-10 and/or by the action of activated transforming growth factor (TGF)-β in vitro. The results can explain stimulation and increase of CD4+ TH2 type cells in patients entering the treatment protocol with more than 200 CD4+ cells as well as the direct clinical improvement by suppressing inflammatory events in vivo.
Unable to display preview. Download preview PDF.
- 8.Brüster HT, Holder A, Illes A, Kuntz BME, Lehnert E, Molling R, Scheja JW, Schneider M (1993) Langzeitstudie einer Therapie mittels lymphozytärer Autovakzine bei HIV-infizierten Patienten. In: Scharrer I, Schramm W (eds) 23. Hämophilie-Symposium, Hamburg 1992. Springer, Berlin Heidelberg New York, pp 68–73Google Scholar